Bajcsy-Zsilinszky Hospital Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2012
NCT01667536
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Bajcsy-Zsilinszky Hospital, Department of Urology | Bajcsy-Zsilinszy Hospital | Bankstown-Lidcombe Hospital, Sydney

Active Ingredients

Drugs in Phase 3 Trials (1)

tanezumab (1 trial)

Drugs in Phase 2 Trials (2)

99mtc mip 1404 (1 trial)

human fecal microbiota (Reybota) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cancer Pain (Phase 3)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Inflammatory Bowel Diseases (Phase 2)

Intestinal Diseases (Phase 2)

Musculoskeletal Pain (Phase 3)

Neoplasm Metastasis (Phase 3)

Prostatic Neoplasms (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3